Joshua McFarlane, MD
Hematology & Oncology · Richmond, VANPI 1184847055
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 274 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,377, more than ten times the $52 reported in 2019.
Across 274 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$664
- Novartis$638
- Pfizer$436
- Johnson & Johnson$341
- Merck$314
- Ipsen Biopharmaceuticals, Inc$241
- plus $3K from 48 others
Across 128 payments — averaging $3005.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$234K
- Merck$79K
- E.r. Squibb & Sons, L.L.C.$65K
- Mirati Therapeutics, Inc.$6K
- F. Hoffmann-la Roche AG$951
What the payments were for
- Food & beverage$5,81397%
- Education$1493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,962 in reported general payments places this provider in the 80th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 58 | $1,028,703 |
| PomalystPomalidomide | 34 | $770,215 |
| CalquenceAcalabrutinib Maleate | 36 | $457,951 |
| ImbruvicaIbrutinib | 28 | $445,059 |
| IbrancePalbociclib | 23 | $333,987 |
| VenclextaVenetoclax | 36 | $213,431 |
| BesremiRopeginterferon Alfa-2b-Njft | 13 | $140,929 |
| EliquisApixaban | 166 | $127,878 |
| Imatinib Mesylate | 35 | $73,857 |
| XareltoRivaroxaban | 49 | $47,073 |
| OxycontinOxycodone Hcl | 17 | $26,507 |
| Abiraterone Acetate | 14 | $15,192 |
| Ondansetron Hcl | 58 | $8,128 |
| Oxycodone Hcl | 131 | $3,644 |
| Anagrelide Hcl | 30 | $3,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $103 | $1,028,70358 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $223 | $770,21534 claims |
| PfizerIbrance, Eliquis | $436 | $461,865189 claims |
| AstraZenecaCalquence | $664 | $457,95136 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $50 | $445,05928 claims |
| AbbVieVenclexta | $65 | $213,43136 claims |
| Pharmaessentia USA CorporationBesremi | $24 | $140,92913 claims |
| Johnson & JohnsonXarelto | $341 | $47,07349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Richmond
- Victor YazbeckRichmond$190K
- Attique SamdaniRichmond$104K
- Elke FriedmanRichmond$23K
- James KhatcheressianRichmond$23K
- Rachit KumarRichmond$12K
- Gisa SchunnRichmond$8K
- Asit PaulRichmond$7K
- Pablo GonzalezRichmond$6K
- Hashim MannRichmond$6K
- Ruby KochharHampton$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.